These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 7934135)

  • 1. Therapy with recombinant human erythropoietin in patients with myelodysplastic syndromes.
    Stone RM; Bernstein SH; Demetri G; Facklam DP; Arthur K; Andersen J; Aster JC; Kufe D
    Leuk Res; 1994 Oct; 18(10):769-76. PubMed ID: 7934135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of anemia in low risk myelodysplastic syndromes with granulocyte-macrophage colony-stimulating factor plus recombinant human erythropoietin.
    Economopoulos T; Mellou S; Papageorgiou E; Pappa V; Kokkinou V; Stathopoulou E; Pappa M; Raptis S
    Leukemia; 1999 Jul; 13(7):1009-12. PubMed ID: 10400415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of response to treatment with human recombinant erythropoietin in myelodysplastic syndromes.
    Stenke L; Wallvik J; Celsing F; Hast R
    Leukemia; 1993 Sep; 7(9):1324-7. PubMed ID: 8371582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subcutaneous recombinant human erythropoietin for the treatment of anemia in myelodysplastic syndromes.
    Ghio R; Balleari E; Ballestrero A; Gatti AM; Mareni C; Massa G; Patrone F; Sessarego M; Timitilli S
    Acta Haematol; 1993; 90(2):58-64. PubMed ID: 8285019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to recombinant human erythropoietin in patients with myelodysplastic syndromes.
    Stasi R; Brunetti M; Bussa S; Conforti M; Di Giulio C; Crescenzi A; Terzoli E; Vecchione A; Pagano A
    Clin Cancer Res; 1997 May; 3(5):733-9. PubMed ID: 9815743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical efficacy analysis of recombinant human erythropoietin in the treatment of lower-risk myelodysplastic syndromes].
    Zhang H; Qin T; Xu Z; Fang L; Pan L; Hu N; Qu S; Zhang Y; Xiao Z
    Zhonghua Xue Ye Xue Za Zhi; 2014 Jan; 35(1):18-23. PubMed ID: 24602726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacologic doses of recombinant human erythropoietin in the treatment of myelodysplastic syndromes.
    Stein RS; Abels RI; Krantz SB
    Blood; 1991 Oct; 78(7):1658-63. PubMed ID: 1912554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimization of recombinant human erythropoietin therapy after allogeneic hematopoietic stem cell transplantation.
    Baron F; Sautois B; Baudoux E; Matus G; Fillet G; Beguin Y
    Exp Hematol; 2002 Jun; 30(6):546-54. PubMed ID: 12063021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Weekly standard doses of rh-EPO are highly effective for the treatment of anemic patients with low-intermediate 1 risk myelodysplastic syndromes.
    Balleari E; Clavio M; Arboscello E; Bellodi A; Bruzzone A; Del Corso L; Lucchetti MV; Miglino M; Passalia C; Pierri I; Ponassi I; Oneto C; Racchi O; Scudeletti M; Vignolo L; Zoppoli G; Gobbi M; Ghio R
    Leuk Res; 2011 Nov; 35(11):1472-6. PubMed ID: 21794914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
    Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
    Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serial changes in endogenous erythropoietin levels in patients with myelodysplastic syndromes and aplastic anemia undergoing erythropoietin treatment.
    Yoshida Y; Anzai N; Kawabata H; Kohsaka Y; Okuma M
    Ann Hematol; 1993 Apr; 66(4):175-80. PubMed ID: 8485205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current use of recombinant human erythropoietin (r-huEPO) in the management of symptomatic anaemia in patients with myelodysplastic syndromes (MDS).
    Marques da Costa R
    Sangre (Barc); 1994 Apr; 39(2):105-10. PubMed ID: 8059287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant human erythropoietin in patients with myelodysplastic syndrome and myelofibrosis.
    Mohr B; Herrmann R; Huhn D
    Acta Haematol; 1993; 90(2):65-70. PubMed ID: 8285020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of recombinant human erythropoietin in the treatment of refractory anemias without excess of blasts in myelodysplastic syndromes.
    Isnard F; Najman A; Jaar B; Fenaux P; Baillou C; Khoury E; Labopin M; Laporte JP; Woler M; Gorin NC
    Leuk Lymphoma; 1994 Jan; 12(3-4):307-14. PubMed ID: 8167562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose recombinant human erythropoietin for treatment of anemia in myelodysplastic syndromes and paroxysmal nocturnal hemoglobinuria: a pilot study.
    Stebler C; Tichelli A; Dazzi H; Gratwohl A; Nissen C; Speck B
    Exp Hematol; 1990 Dec; 18(11):1204-8. PubMed ID: 2226680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant human erythropoietin in the treatment of myelodysplastic syndromes. An interim report.
    Aloe Spiriti MA; Petti MC; Latagliata R; Avvisati G; De Gregoris C; Proia S; Fazi P; Jaalouk G; Mancini M; Spadea A
    Haematologica; 1993; 78(2):123-6. PubMed ID: 8349188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of subcutaneously administered human recombinant erythropoietin on erythropoiesis in patients with myelodysplasia.
    van Kamp H; Prinsze-Postema TC; Kluin PM; den Ottolander GJ; Beverstock GC; Willemze R; Fibbe WE
    Br J Haematol; 1991 Aug; 78(4):488-93. PubMed ID: 1911340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of a single, weekly dose of recombinant erythropoietin in myelodysplastic syndromes.
    Musto P; Falcone A; Sanpaolo G; Bodenizza C; La Sala A; Perla G; Carella AM
    Br J Haematol; 2003 Jul; 122(2):269-71. PubMed ID: 12846896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant human erythropoietin for treatment of myelodysplastic syndromes.
    Rafanelli D; Grossi A; Longo G; Vannucchi AM; Bacci P; Ferrini PR
    Leukemia; 1992 Apr; 6(4):323-7. PubMed ID: 1588794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study.
    Balleari E; Rossi E; Clavio M; Congiu A; Gobbi M; Grosso M; Secondo V; Spriano M; Timitilli S; Ghio R
    Ann Hematol; 2006 Mar; 85(3):174-80. PubMed ID: 16408206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.